Skip to content

Advertisement

  • Poster presentation
  • Open Access

Permanent neonatal diabetes due to a heterozygous INS mutation

  • 1,
  • 1,
  • 2 and
  • 2
International Journal of Pediatric Endocrinology20152015 (Suppl 1) :P29

https://doi.org/10.1186/1687-9856-2015-S1-P29

  • Published:

Keywords

  • Metabolic Acidosis
  • Metabolic Control
  • Insulin Pump
  • Neonatal Diabetes
  • Severe Metabolic Acidosis

Permanent Neonatal Diabetes Mellitus (PNDM) is a rare disorder where patient presents with diabetes within the first few months of life without autoantibodies associated with type 1 diabetes. The majority of PNDM cases have INS, ABCC8 or KCNJ11 mutations. We present a PNDM case with INS mutation. The proband is a second child of three siblings without family history of diabetes. She was born at term via emergency lower segment caesarean section with good APGAR score. Her birth weight was 2.0kg (<3rd percentile), length 49cm (50th percentile), and head circumference 34cm (50th percentile). She was discharged well at day 3 of life, but readmitted at day 17 of life with hyperglycaemia, sepsis and severe metabolic acidosis, requiring insulin infusion. Despite clinical improvement and resolving sepsis, she remained hyperglycaemic and hence neonatal diabetes was suspected. Her GAD-65 and ICA-512 antibodies were negative. HbA1c and c-peptide at diagnosis were 7.9% and 38 pmol/L (normal range: 297.9–1324) respectively. She was still hyperglycaemic despite receiving total daily insulin (TDI) of 1.5U/kg/day, but not ketotic. She was discharged after 20 days of hospitalization with insulatard administered three times daily (TDI 1.2U/kg/day). During the first 8 months of diagnosis, her metabolic control was good (HbA1c 6.7 - 7.6%) despite low insulin requirement, as low as 0.4U/kg/day. Her metabolic control deteriorated since then (HbA1c 11.9 - 13.2%), with TDI doses ranging 0.7 - 0.9 U/kg/day. Rapid acting insulin was not used due to episodes of hypoglycaemia and unpredictable eating habit and activity levels during her toddler years. Direct DNA sequencing revealed she is heterozygous for p.A24D INS mutation. This mutation has been reported in the literature and known to disrupt preproinsulin processing. Recent evaluation at 51 month showed, negative anti-islet cell antibodies and c-peptide of <30pmol/L (normal range: 297.9–1324). Currently, her developmental milestone is appropriate for her age. However, her height and weight were both below the 3rd centiles. She was recently started on insulin pump to improve her metabolic control and growth.

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Authors’ Affiliations

(1)
Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
(2)
Department of Pediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Copyright

© Long et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement